New Drug Manufacturing Rules 2026: India’s 3-Tier Change Classification & DCGI Licensing Overhaul

March 19, 2026 Posted by India Briefing Written by Archana Rao Reading Time: 3 minutes

India has taken crucial steps towards its pharmaceutical regulatory architecture through two complementary initiatives: proposed amendments to the Drugs Rules, 1945, under the Drugs and Cosmetics Act, 1940, and a parallel push by the Drugs Controller General of India (DCGI) to standardize drug licensing practices across states. Together, these measures aim to enhance quality consistency, transparency, and scientific rigor in India’s drug manufacturing and approval processes.

Proposed amendments: Structured oversight of drug manufacturing changes

On March 9, 2026, the central government issued draft rules to introduce a formalized framework for managing post-approval changes in drug manufacturing and product specifications. Developed in consultation with the Drugs Technical Advisory Board, the draft is currently open for stakeholder feedback, with a 30-day window for public comments before finalization.

At its core, the amendment seeks to address a longstanding regulatory gap: the absence of a standardized mechanism to evaluate and monitor changes made by manufacturers after a drug has been approved.

Key regulatory shift: Mandatory change reporting

Under the proposed framework, drug manufacturers in India will be required to notify the relevant licensing authority in writing whenever modifications are made to critical aspects of a drug product, including:

Stay ahead of regulatory change and elevate performance across your pharmaceutical operations

Manufacturing processes
Composition (including excipients)
Packaging systems
Shelf life
Product specifications
Testing methodologies
Regulatory documentation

This requirement spans multiple licensing provisions under the Drugs Rules, 1945, ensuring uniform applicability across different categories of pharmaceutical manufacturing.

Three-tier classification system for India’s drug manufacturing framework

To streamline regulatory oversight, the draft introduces a risk-based classification model:

Category	Nature of change	Regulatory requirement
Level I (major)	Significant impact on identity, strength, quality, purity, or potency	Prior approval mandatory before implementation
Level II (moderate)	Moderate impact on product quality attributes	Prior approval required
Level III (minor)	Minimal or no significant impact on quality	No prior approval; annual reporting required

Notably, even minor changes affecting shelf life remain subject to additional scrutiny. In certain cases, manufacturers must also inform authorities within 30 days of implementing changes, reinforcing post-market surveillance.

Impact on drug licensing conditions and compliance systems

The draft rules further propose revisions to conditions attached to manufacturing licenses (e.g., Forms 25 and 28), mandating disclosure of changes in production processes, formulation, and packaging. Where such changes fall under major or moderate categories, prior regulatory clearance becomes a prerequisite.

For pharmaceutical companies, this translates into a need for:

Robust internal change classification systems
Strengthened regulatory reporting protocols
Alignment of quality assurance frameworks with the new risk-based approach
Enhanced documentation and audit trails

Parallel reform: Uniform drug licensing across states

The DCGI has also introduced a nationwide directive to harmonize drug licensing practices. This includes the rollout of a comprehensive guidance document mandating a dossier-based evaluation system for all manufacturing applications.

Historically, India’s decentralized licensing structure allowed state authorities considerable discretion, often resulting in inconsistent evaluation standards. This lack of uniformity created variability in how drug quality, safety, and efficacy were assessed.

The new framework seeks to eliminate such disparities by enforcing a single, standardized benchmark across all states and Union Territories, critical for a country widely regarded as a global hub for generic drug manufacturing.

CLICK HERE: Registering a Pharmaceutical Company in India: How to Obtain CDSCO & Drug License Approvals

Dossier-based drug licensing evaluation

Another central feature of the latest drug licensing reform is the shift to a structured dossier-based review system. Manufacturers must now submit comprehensive data through the Online National Drugs Licensing System, enabling more consistent and evidence-based regulatory decisions.

The guidance introduces a 41-point checklist, divided into two:

Administrative and infrastructure requirements (e.g., facility layout)
Technical and scientific data (e.g., stability studies, validation data)

Establish and scale your pharmaceutical business in India with end-to-end regulatory and market entry support

A key element is Form 29, which functions as a test license, allowing manufacturers to produce limited batches for analytical and stability testing under regulatory supervision. This ensures that critical data supporting product approval is generated in compliant and controlled conditions.

Continuity between the two reforms for drug manufacturing

Both the draft amendments and the DCGI’s licensing standardization initiative are aligned in their regulatory intent:

Risk-based oversight: The classification of manufacturing changes mirrors the structured, evidence-based approach of dossier evaluations.
Enhanced documentation: Both reforms emphasize comprehensive data submission and traceability.
Regulatory harmonization: While one targets post-approval changes, the other standardizes pre-approval licensing.
Quality assurance: Each measure reinforces consistent application of Good Manufacturing Practices (GMP) across jurisdictions.

Implementation challenges and industry readiness

Despite their strategic alignment, implementation may present challenges, particularly for small and mid-sized drug manufacturers. Compliance with enhanced documentation, testing, and infrastructure requirements may require significant capital investment and technical capability.

There is also a risk that firms may initially focus on procedural compliance rather than substantive quality improvements. This underscores the importance of effective enforcement and capacity-building measures by regulators.

Conclusion

Taken together, these reforms represent a coordinated effort to modernize India’s pharmaceutical regulatory ecosystem. By integrating structured change management with uniform licensing standards, the government is moving toward a more predictable, transparent, and scientifically robust framework.

If effectively implemented, these measures will not only strengthen domestic quality assurance but also reinforce India’s credibility as a reliable global supplier of pharmaceuticals.

About Us

India Briefing is one of five regional publications under the Asia Briefing brand. It is supported by Dezan Shira & Associates, a pan-Asia, multi-disciplinary professional services firm that assists foreign investors throughout Asia, including through offices in Delhi, Mumbai, and Bengaluru in India. Dezan Shira & Associates also maintains offices or has alliance partners assisting foreign investors in China, Hong Kong SAR, Vietnam, Indonesia, Singapore, Malaysia, Mongolia, Dubai (UAE), Japan, South Korea, Nepal, The Philippines, Sri Lanka, Thailand, Italy, Germany, Bangladesh, Australia, United States, and United Kingdom and Ireland.

For a complimentary subscription to India Briefing’s content products, please click here. For support with establishing a business in India or for assistance in analyzing and entering markets, please contact the firm at india@dezshira.com or visit our website at www.dezshira.com.